Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Re-directed immunotherapy

A therapeutic agent, targeted technology, applied in immunoglobulin, anti-animal/human immunoglobulin, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve the elusive clinical success, etc. question

Active Publication Date: 2014-02-05
THE UNIV OF BIRMINGHAM
View PDF15 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, only a handful of ADCs are currently in late stages of clinical development, and clinical success for these has proven elusive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Re-directed immunotherapy
  • Re-directed immunotherapy
  • Re-directed immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0282] Example 1: Stimulation of T cells by Cetuximab-NLVMVATV (SEQ ID NO: 21) conjugate

[0283] overview

[0284] We exposed breast cancer cells to an agent containing Cetuximab conjugated to HLA-B7 peptides with and without a cleavage site. Subsequent exposure to T cells led to the generation of a T cell response when the breast cancer cells were exposed to an agent containing the cleavage site.

[0285] result

[0286] MDA.MB.231 cells, which are often used as a model of breast cancer, were transduced with the MMP14 gene to ensure the expression of MMP14 protein in the cells. Unconjugated (1) or coupled with RPHERNGFTVL (SEQ ID No:32), HLA-B7 peptide (2), coupled with NLVPMVATV (SEQ ID No:21) without MMP14 cleavage sequence (3) or with Target cells (1×10 5 ) after staining, the stained cells were incubated overnight. The next day, cells were washed, and NLV-specific T cells were added to the culture (1 × 10 4 ), and incubated overnight. Supernatants were collected...

Embodiment 2

[0288] Example 2: Stimulation of CD4 by Retuximab-DYSNTHSTRYV (SEQ ID NO:55) conjugate + T cells

[0289] overview

[0290] We exposed B-lymphoblastoid cells (B-LCL) to an agent containing Retuximab conjugated to the cytomegalovirus class II HLA-restricted peptide DYSNTHSTRYV (SEQ ID NO:55) with and without a cleavage site. Subsequently, when B-LCL cells are exposed to agents containing cleavage sites, exposure to CD4 + T cells lead to the generation of a T cell response.

[0291] result

[0292] Conjugate unrelated mismatched peptide RPHERNGFTVL (SEQ ID No:32) without protease cleavage sequence, HLA-B7 peptide (1), and irrelevant mismatched class I HLA peptide VLEEETSVML (SEQ ID No:316) with protease cleavage sequence , HLAA-A2 peptide (2), the related peptide DYSNTHSTRYV (SEQ ID No:55) (3) without the protease cleavage sequence or the related peptide DYSNTHSTRYV (SEQ ID No:55) (4) including the protease cleavage sequence, Rituximab will After staining of B-LCL cel...

Embodiment 3

[0294] Example 3: Standard Operating Procedure for Chemically Conjugating Cysteinylated Peptides and Antibodies

[0295] 1. Dissolve cysteinylated peptide in DMSO to a final concentration of 5 mg / ml.

[0296] 2. Weigh 1 mg of sulfosuccinimide 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (thio-SMCC) and dissolve in 500 μl of phosphate-buffered saline (PBS )middle.

[0297] a. Other heterobifunctional cross-linking agents such as thiosuccinimide 6-(3'-[2-pyridyl dithio]-propionamido) hexanoate ( Thio-LC-SPDP ) and N-[β-maleimide propionic acid] hydrazide, trifluoroacetate ( BMHP ).

[0298] 3. Add 20 μl antibody (1 mg / ml, 20 μg antibody) to the dissolved thio-SMCC and incubate at room temperature for 1 hour.

[0299] 4. The protein G column (GE Healthcare) was first washed by centrifuging the column at 13,000 rpm for 30 seconds to remove ethanol (storage buffer).

[0300] 5. Add 500 μl PBS and mix protein G beads well, then centrifuge at 13,000 rpm for 30 seconds. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.

Description

technical field [0001] The present invention relates to immunotherapeutic agents. In particular, it relates to agents that can be used to prevent or treat disorders characterized by the presence of unwanted cells, such as cells that cause cancer or other diseases. Background technique [0002] Immunotherapeutic strategies for targeting malignant diseases are an active area of ​​translational clinical research and have been underway for decades. Current models require that cancers represent functional or constitutional immune deficiencies that can be treated with immunotherapeutic manipulation of the host. These efforts can be broadly divided into two groups. The first group enhances or supports endogenous antitumor immunity through methods such as vaccination, cytokine support (IL-2, IFNγ), or reducing the immunosuppressive environment (ipilimumab), while the second Two groups seek to repair absolute deficiencies with functional immune response components (passive immunot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61K39/12A61P37/00
CPCA61K45/06A61K39/08A61K39/12A61K47/4833A61K39/3955A61K39/145C07K16/2887A61K47/48276A61K39/235A61K47/48415C07K2317/622A61K39/245A61K47/48584A61K2039/585A61K2039/627C07K16/32A61K38/2026A61K2039/6056A61K38/204A61K2039/505A61K38/2013A61K47/4863C12N2710/16134A61K47/6889A61K47/646A61K47/6811A61K47/6855A61K47/6867A61P11/06A61P25/00A61P25/28A61P31/04A61P35/00A61P37/00A61P37/04A61P37/06A61P37/08A61P9/00A61P3/10C07K16/3007C07K16/30C07K16/2806C07K16/2878C07K16/2875C07K14/70539C07K16/3015C07K16/3038C07K16/3053C07K16/3023C07K16/3046C07K14/11C07K14/045C07K14/05C07K14/12C07K14/04C07K14/095A61K47/6869A61K47/6863A61K47/6857A61K47/6865A61K47/6861A61K47/6853A61K47/6859A61K47/6851A61K39/39558C07K14/005C07K16/2863C07K2317/24C07K2319/33C07K2319/50C12N7/00
Inventor 马克·科博尔德大卫·米勒德
Owner THE UNIV OF BIRMINGHAM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com